ETH-155008 / Shengke Pharmaceuticals - LARVOL DELTA

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Shengke Pharmaceuticals (Jiangsu) Limited, China | Trial completion date: Mar 2025 ➔ Jun 2026 | Trial primary completion date: Feb 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - P1a/1b | N=9 | Terminated | Sponsor: Shengke Pharmaceuticals Pty Ltd | N=67 ➔ 9 | Recruiting ➔ Terminated; The reasons for early termination is due to slow recruitment

Enrollment change • Trial termination • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • FLT3 • RB1

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Shengke Pharmaceuticals (Jiangsu) Limited, China

New P1 trial • Acute Myelogenous Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CDK4

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - P1a/1b | N=67 | Recruiting | Sponsor: Shengke Pharmaceuticals Pty Ltd | Active, not recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • FLT3 • RB1

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - P1a/1b | N=9 | Active, not recruiting | Sponsor: Shengke Pharmaceuticals Pty Ltd | Recruiting ➔ Active, not recruiting | N=67 ➔ 9

Enrollment change • Enrollment closed • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • FLT3 • RB1

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - P1a/1b; N=67; Recruiting; Sponsor: Shengke Pharmaceuticals Pty Ltd; Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • FLT3

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (clinicaltrials.gov) - P1a/1b; N=67; Not yet recruiting; Sponsor: Shengke Pharmaceuticals Pty Ltd

New P1 trial • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • FLT3